Six prominent members of the US House of Representatives including Katie Porter, who has previously been committed to regulating the pharmaceutical industry, have sent a letter to the US Federal Trade Commission (FTC) encouraging this authority to investigate Novo Nordisk, Sanofi and Eli Lilly, according to media Endpoints News.
In the letter, the six Democrats detail that the firms raised their insulin prices at the same time, which caused the price to nearly double between 2012 and 2016. For this reason, it should be investigated whether the involved parties had agreed on this in advance, the Democrats state.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.